Viatris (VTRS) Long-Term Debt Repayments (2020 - 2025)
Viatris' (VTRS) quarterly Long-Term Debt Repayments came in at $100000.0 in Q4 2025, down 99.99% year-on-year from $1.4 billion in Q4 2024, and down 99.99% quarter-over-quarter from $1.4 billion in Q4 2024.
Viatris (VTRS) Long-Term Debt Repayments (2020 - 2025) Analysis & Trends
Viatris' Long-Term Debt Repayments history runs 6 years deep, the most recent figure standing at $100000.0 for Q4 2025.
- On a quarterly basis, Long-Term Debt Repayments fell 99.99% year-over-year to $100000.0 in Q4 2025; TTM through Dec 2025 was $2.9 billion, a 21.58% decrease from a year earlier, with the FY2025 full-year figure at $100000.0, down 100.0% from the prior year.
- Long-Term Debt Repayments fell to $100000.0 in Q4 2025 per VTRS's latest filing, from $1.4 billion in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $2.3 billion in Q2 2021 and bottomed at $100000.0 in Q1 2022.
- The 5-year median for Long-Term Debt Repayments is $801.7 million (2024), against an average of $986.8 million.
- Across the five-year window, Long-Term Debt Repayments surged 750000.0% in 2023 and plunged 99.99% in 2025, its largest moves.
- Year by year, Long-Term Debt Repayments stood at $600000.0 in 2021, then surged by 116666.67% to $700.6 million in 2022, then retreated by 28.62% to $500.1 million in 2023, then soared by 174.81% to $1.4 billion in 2024, then plunged by 99.99% to $100000.0 in 2025.
- Per Business Quant, the three latest VTRS Long-Term Debt Repayments figures stand at $100000.0 (Q4 2025), $1.4 billion (Q4 2024), and $1.5 billion (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 23.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -478.39 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 1.37 Bn |
| Dec 31, 2024 | 1.37 Bn |
| Sep 30, 2024 | 1.54 Bn |
| Sep 30, 2024 | 1.54 Bn |
| Jun 30, 2024 | 801.70 Mn |
| Jun 30, 2024 | 801.70 Mn |
| Dec 31, 2023 | 500.10 Mn |
| Dec 31, 2023 | 500.10 Mn |
| Mar 31, 2023 | 750.10 Mn |
| Mar 31, 2023 | 750.10 Mn |
| Dec 31, 2022 | 700.60 Mn |
| Dec 31, 2022 | 700.60 Mn |
| Sep 30, 2022 | 1.17 Bn |
| Sep 30, 2022 | 1.17 Bn |
| Jun 30, 2022 | 1.79 Bn |
| Jun 30, 2022 | 1.79 Bn |
| Mar 31, 2022 | 100,000.00 |
| Mar 31, 2022 | 100,000.00 |